


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



# 華控康泰集團有限公司

## Kontafarma China Holdings Limited

*(Incorporated in the Cayman Islands with limited liability)*

(Stock Code: 1312)

### PROFIT WARNING

This announcement is made by Kontafarma China Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment of the latest unaudited consolidated management accounts of the Group for the six months ended 30 June 2024 (the “**Period**”), the Group is expected to record a consolidated net loss in the range of approximately HK\$4 million to HK\$8 million for the Period, compared to the Group’s consolidated net profit of approximately HK\$21.4 million for the six months ended 30 June 2023.

The aforesaid net loss expectedly to be recorded for the Period when compared to the net profit recorded in respect of the corresponding period in 2023 was primarily due to the reason that a one-off gain of approximately HK\$110.5 million was recorded by the Group for the disposal of subsidiaries in respect of the corresponding period in 2023 and no such gain was recorded in the Period. Nevertheless, the overall revenue and gross profit generated from ordinary course of business in both pharmaceutical and fitness segments of the Group are expected to record an increase for the Period when compared to the corresponding period in 2023, coupled with a decrease in various expenses as a result of effective costs control measures implemented by the Group.

The information in this announcement is based on a preliminary assessment by the management of the Company according to the unaudited consolidated management accounts of the Group for the Period. Such information has not been finalised, audited or reviewed by the Company's independent auditor, and has not been confirmed by the audit committee of the Board. Shareholders and potential investors are advised to refer to the details in the results announcement of the Company for the Period, which is expected to be published on or around 28 August 2024. There may be changes or adjustments following review of the unaudited management accounts by the independent auditor of the Company.

**Shareholders and potential investors should exercise caution when dealing in the shares or other securities of the Company.**

By order of the Board of  
**Kontafarma China Holdings Limited**  
**Wang Feifei**  
*Chairman*

Hong Kong, 20 August 2024

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Feifei (Chairman and President), Ms. Qiao Linna, Ms. Guo Zixiu (Financial Controller) and Mr. Liu Jiankun; one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.*